The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity.

Studied

A kidney-safety analysis reported kidney impairment, dehydration and low blood pressure. One retatrutide participant had serious acute kidney injury, possibly secondary to COVID-19.

Who / model

Exploratory analysis of two retatrutide trials included 281 participants with type 2 diabetes and 338 with overweight or obesity without diabetes, followed for 36 and 48 weeks. Both compared placebo; the diabetes trial also included dulaglutide.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

At the highest studied dose, urine albumin-to-creatinine ratio was 37.0% lower versus placebo in diabetes and 31.5% lower in obesity. Estimated kidney filtration was unchanged versus placebo in diabetes but increased in obesity. Absolute albumin reductions were modest.

Limits

The analysis was exploratory, without adjustment for multiple comparisons. Few participants had existing kidney disease, follow-up was short, and no kidney outcome events occurred; prevention of kidney failure was not established.

Read summary source ↗ · Prepared 9/22/2026 · AI-assisted, source-based summary